Proton Pump Inhibitor Use Linked to Asthma Risk in Children
Findings showed that children who were initiated on PPIs were 57% more likely to be diagnosed with asthma.
Asthma
In Utero Exposure to Antibiotics May Up Asthma Risk in Vaginally Born
Antibiotic exposure in second to third trimester, but not in first trimester, linked to increased odds of asthma at age 11
Severe Asthma Management
Recommendations for the management of severe asthma from the Global Initiative for Asthma (GINA).
Asthma Prevalence May Be Higher in Elderly With Behavioral Health Issues
Because of the prevalence of behavioral health issues in elderly patients with asthma, appropriate behavioral health treatment may improve patient outcomes.
Pulse Oximetry, Vital Signs May Predict Hospital LOS in Pediatric Asthma Exacerbations
Heart rate, respiratory rate, and oxygen saturation (SpO2) levels with percentile-based cutoffs can predict the risk of prolonged hospitalization in pediatric asthma exacerbations.
Adding Umeclidinium to ICS/LABA Improves Lung Function, Exacerbation Rate in Asthma
Patients with asthma that is poorly controlled by ICS/LABA therapy may experience improvement in lung function with the addition of umeclidinium and/or doubling of the corticosteroid fluticasone furoate.
Adding Reslizumab May Benefit Uncontrolled Chronic Rhinosinusitis With Nasal Polyps
Adding reslizumab to mometasone furoate enhanced clinical benefits of the intranasal corticosteroid alone in patients with uncontrolled chronic rhinosinusitis with nasal polyps and peripheral eosinophilia.
Dupilumab Demonstrates Long-Term Efficacy, Safety for Improving Asthma Control
Treatment with monoclonal antibody and dual IL-4/IL-13 inhibitor dupilumab was well tolerated and associated with sustained improvement in asthma control for up to 96 weeks
Dupilumab Reduces Severe Asthma Exacerbations, With/Without Reduction in FeNO
Dupilumab significantly reduced severe asthma exacerbations and improved prebronchodilator FEV1 in patients with baseline FeNO greater than or equal to 25 ppb with/without substantial FeNO reduction.
Benralizumab Achieves Clinically Meaningful Improvements in Asthma, Nasal Polyposis
The majority of patients with asthma and nasal polyposis who were treated with benralizumab were considered “comprehensive responders.”
